Following the discovery of the critical pathogenetic role of tumor necrosis factor-α (TNF-α) in inflammatory bowel disease (IBD), monoclonal anti-TNFα antibodies have been developed and successfully adopted in clinical practice [5]. The gene discussed is TNF; the disease is inflammatory bowel disease.